Curran Simpson Biography and Net Worth

CEO of REGENXBIO

Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.

What is Curran Simpson's net worth?: The estimated net worth of Curran Simpson is at least $1.99 million as of October 9th, 2025. Simpson owns 216,162 shares of REGENXBIO stock worth more than $1,988,907 as of April 21st. This net worth evaluation does not reflect any other assets that Simpson may own. Learn More about Curran Simpson's net worth.
How do I contact Curran Simpson?: The corporate mailing address for Simpson and other REGENXBIO executives is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. REGENXBIO can also be reached via phone at (240) 552-8181 and via email at [email protected]. Learn More on Curran Simpson's contact information.
Has Curran Simpson been buying or selling shares of REGENXBIO?: Curran Simpson has not been actively trading shares of REGENXBIO during the last quarter. Most recently, Curran Simpson sold 20,811 shares of the business's stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $12.62, for a transaction totalling $262,634.82. Following the completion of the sale, the chief executive officer now directly owns 216,162 shares of the company's stock, valued at $2,727,964.44. Learn More on Curran Simpson's trading history.
Who are REGENXBIO's active insiders?: REGENXBIO's insider roster includes Allan Fox (Director), Kenneth Mills (CEO), Kenneth Mills (CEO), Steve Pakola (Insider), and Curran Simpson (CEO). Learn More on REGENXBIO's active insiders.
Are insiders buying or selling shares of REGENXBIO?: In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 61,895 shares worth more than $632,593.44. The most recent insider tranaction occured on March, 10th when insider Steve Pakola sold 5,124 shares worth more than $53,033.40. Insiders at REGENXBIO own 12.8% of the company. Learn More about insider trades at REGENXBIO.
Information on this page was last updated on 3/10/2026.

Curran Simpson Insider Trading History at REGENXBIO

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/9/2025	Sell	20,811	$12.62	$262,634.82	216,162
9/29/2025	Sell	7,624	$10.03	$76,468.72	236,973
9/10/2025	Sell	7,734	$10.02	$77,494.68	244,597
8/1/2024	Sell	100	$15.00	$1,500.00	170,037
7/29/2024	Sell	9,648	$15.04	$145,105.92	170,137
1/14/2021	Sell	13,312	$50.01	$665,733.12	19,448
1/7/2021	Sell	5,185	$50.01	$259,301.85	22,933
1/17/2020	Sell	5,922	$50.00	$296,100.00	25,570
5/28/2019	Sell	18,000	$50.00	$900,000.00	57,500
2/25/2019	Sell	5,300	$54.05	$286,465.00	44,800
2/5/2019	Sell	43,832	$50.08	$2,195,106.56	47,950
11/16/2018	Sell	32,882	$63.76	$2,096,556.32
10/16/2018	Sell	62,309	$60.85	$3,791,502.65	86,017
3/13/2018	Sell	25,000	$33.00	$825,000.00
12/22/2017	Sell	30,000	$33.03	$990,900.00	69,500
12/7/2017	Sell	21,890	$30.04	$657,575.60	41,390
12/4/2017	Sell	110	$30.00	$3,300.00	39,610
11/27/2017	Sell	2,000	$29.31	$58,620.00	41,500

Curran Simpson Buying and Selling Activity at REGENXBIO

REGENXBIO Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Today's Range

Now: $9.10

$9.03

$9.59

50 Day Range

MA: $8.66

$7.76

$10.38

2 Week Range

Now: $9.10

$6.72

$16.19

Volume

433,992 shs

Average Volume

908,416 shs

Market Capitalization

$469.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14